Evidence map›Paper›PMID 30101676›Full record

ArticleTissue engineering. Part A2019

The Osteoinductive Effect of Controlled Bone Morphogenic Protein 2 Release Is Location Dependent.

Maurits G L Olthof, Lichun Lu, Marianna A Tryfonidou, Loek D Loozen, Behdad Pouran, Michael J Yaszemski, Björn P Meij, Wouter J A Dhert, Jacqueline Alblas, Diederik H R Kempen

Abstract read
In one paragraph

Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maurits G L Olthof1 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Lichun Lu2 Department of Physiology and Biomedical Engineering and Mayo Clinic College of Medicine, Rochester, Michigan.
Marianna A Tryfonidou4 Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Loek D Loozen1 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Behdad Pouran1 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Michael J Yaszemski2 Department of Physiology and Biomedical Engineering and Mayo Clinic College of Medicine, Rochester, Michigan.
Björn P Meij4 Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Wouter J A Dhert1 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Jacqueline Alblas1 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Diederik H R Kempen7 Department of Orthopaedic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

Funding

Injectable Osteoinductive Biodegradable CompositesR01EB003060 · NIBIB · MAYO CLINIC ROCHESTER · PI LU, LICHUN, YASZEMSKI, MICHAEL J · 2003 to 2014
$3.4M
OSTEOINDUCTIVE INJECTABLE DEGRADEABLE POLYMERIC SCAFFOLDR01AR045871 · NIAMS · MAYO CLINIC ROCHESTER · PI YASZEMSKI, MICHAEL J · 1999 to 2008
$2.7M
NIAMS NIH HHS R01 AR045871NIBIB NIH HHS R01 EB003060
6 · The paper itself

Abstract

impact statementThe main challenge in bone morphogenic protein 2 (BMP-2)-based application lies in finding strategies to prolong its biologic activity as it has a short biological half-life. The present study uses a phosphate-modified oligo[(polyethylene glycol) fumarate] hydrogel that can be tuned to achieve differential release profiles of biologically active BMP-2 release. We demonstrate that this platform outperforms Infuse

Indexed as

Bone Morphogenetic Protein 2HydrogelsTissue EngineeringAnimalsBone and BonesDelayed-Action PreparationsHumansMalePolyethylene GlycolsRatsRats, Sprague-DawleyTissue ScaffoldsBMP2 protein, humanBone Morphogenetic Protein 2Delayed-Action PreparationsHydrogelsPolyethylene Glycolsapplication sitesbone morphogenetic protein 2bone tissue engineeringoligo[(polyethylene glycol) fumarate]

Identifiers

PMID30101676
PMCPMC6388716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.